300529 健帆生物
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入1,556,022-29.13%2,677,3211,922,3482,491,4392,675,454
减:营业总成本1,020,308-20.42%1,711,4111,420,6421,550,0451,332,899
    其中:营业成本317,574-22.61%514,608389,456440,106402,064
               财务费用30,73833.65%32,444(33,896)(17,820)(12,438)
               资产减值损失(8,262)53,822.38%(10,844)(28,182)(6,512)(57)
公允价值变动收益30,9229,137.44%1,023--(15)15
投资收益8,748-64.57%42,090--10,52428,704
    其中:对联营企业和合营企业的投资收益------------
营业利润586,381-40.43%1,045,366543,8191,029,4551,417,924
利润总额552,054-42.17%1,006,964521,0201,016,8081,407,218
减:所得税费用100,196-39.57%192,77895,297135,863211,376
净利润451,858-42.72%814,186425,723880,9451,195,841
减:非控股权益(1,372)-51.13%(6,009)(10,769)(8,619)(972)
股东净利润453,230-42.75%820,195436,492889,5641,196,813

市场价值指针
每股收益 (元) *0.590-40.40%1.0500.5501.1201.490
每股派息 (元) *----0.8000.4000.6700.900
每股净资产 (元) *4.1454.42%4.0263.7504.2784.022
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容